Since these guidelines were published, the availability of therapies, such as SGLT2 inhibitors that have shown overwhelming kidney and cardiovascular benefits in albuminuric CKD, has made UACR testing even more imperative irrespective of diabetes status [9]. This evidence concerns the gene SLC5A2 and chronic kidney disease.